Head-to-head evidence
Dostarlimab vs Sasanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline
NCT03739710 · Phase 2 · completed
An open-label platform master study whose posted primary outcome is only the number of participants randomized across sub-studies; no comparative efficacy result for the dostarlimab-containing regimens is reported on the record. With no usable result and no blinding, this is weak evidence.
Next expected readout: November 2026 · NCT05565378 (registry estimate)
Sasanlimab
Developed by Pfizer
NCT04181788 · Phase 1/2 · completed
Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.
Next expected readout: October 2026 · NCT06447662 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Sasanlimab's landscape